...
首页> 外文期刊>Alternative therapies in health and medicine >Renin-Angiotensin-Aldosterone Signaling Inhibitors-Losartan, Enalapril, and Cardosten-Prevent Infarction-induced Heart Failure Development in Rats
【24h】

Renin-Angiotensin-Aldosterone Signaling Inhibitors-Losartan, Enalapril, and Cardosten-Prevent Infarction-induced Heart Failure Development in Rats

机译:肾素-血管紧张素-醛固酮信号传导抑制剂-洛沙坦,依那普利和卡多森预防心梗的大鼠诱发心力衰竭的发展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Context . The activation of the renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathophysiology of congestive heart failure, which is the reason that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin 2 receptor blockers (ARBs) have become established therapies for heart failure. However, it is still not known whether preventive treatment with losartan or enalapril can reduce symptoms of infarction-induced heart failure. Ultra-low dose (ULD) drug therapy is thought to exert specific activity, with a lower chance of side effects.
机译:语境。肾素-血管紧张素-醛固酮系统(RAAS)的激活在充血性心力衰竭的病理生理中起着重要作用,这是血管紧张素转换酶抑制剂(ACEI)和血管紧张素2受体阻滞剂(ARB)成为公认疗法的原因对于心力衰竭。但是,尚不清楚氯沙坦或依那普利的预防性治疗是否可以减轻梗塞性心力衰竭的症状。人们认为超低剂量(ULD)药物疗法具有特定活性,且副作用几率较低。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号